Cyclobutyl benzimidazoles as pde 10 inhibitors
AssigneeMerck Sharp & Dohme Corp.
InventorsScott D. Kuduk, Casey C. McComas, Thomas S. Reger
Life of this patent
Estimating the term…
Abstract
The present invention is directed to substituted cyclobutyl benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Claims21
1-21. (canceled)
A compound of the formula I:
- wherein:
- each R, and Rx independently represent H, OH, halogen, or C1-6alkyl,
- Rc represents H, OH, halogen, —C(R)2OR, or C1-6alkyl,
- R2 is selected from the group consisting of H, O—R, CN, O(CH2)nOR, OCHR(CH2)nOR, SR, SO2R, S(O)R, N(R)2, C(O)N(R)2, C1-3 haloalkyl, O(CH2)nC1-3haloalkyl, O(CH2)nC3-6cycloalkyl, (CH2)nC5-10heterocycle, C1-6alkyl, and C3-10cycloalkyl, said alkyl, cycloalkyl, and heterocycle unsubstituted or substituted with 1 to 3 groups of Ra;
- Ra is selected from the group consisting of:
- (1) halogen,
- (2) hydroxyl,
- (3) C1-6alkyl,
- (4) —(CH2)nO—R,
- (5) (CH2)nC6-10aryl,
- (6) (CH2)nC5-10 heterocycle,
- (7) OC1-5 haloalkyl;
- (8) CO2R;
- (9) C(O)N(R)2;
- (10) (CH2)nC(O)R;
- (11) CN,
- (12) (CH2)nN(R)2;
- (13) (CH2)nC3-6cycloalkyl,
- (14) (CH2)nC1-3 haloalkyl;
- (15) —O—
- n represents 0-4,
- or a pharmaceutically acceptable salt thereof.
The compound according to claim 9 wherein R is methyl.
A compound which is:
- 1-(6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl)-3-(1-methyl-1H-benzo[d]imidazol-2-yl)cyclobutanol,
- 2-(3-(6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl)-3-fluorocyclobutyl)-1-methyl-1H-benzo[d]imidazole,
- 2-((cis)-3-(6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl)cyclobutyl)-1-methyl-1H-benzo[d]imidazole,
- 2-((trans)-3-(6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl)cyclobutyl)-1-methyl-1H-benzo[d]imidazole,
- or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.